<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ame212548" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Animal Model Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">Animal Model Exp Med</journal-id><journal-id journal-id-type="pmc-domain-id">3615</journal-id><journal-id journal-id-type="pmc-domain">animalmod</journal-id><journal-id journal-id-type="publisher-id">AME2</journal-id><journal-title-group><journal-title>Animal Models and Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">2096-5451</issn><issn pub-type="epub">2576-2095</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431596</article-id><article-id pub-id-type="pmcid-ver">PMC12431596.1</article-id><article-id pub-id-type="pmcaid">12431596</article-id><article-id pub-id-type="pmcaiid">12431596</article-id><article-id pub-id-type="pmid">39854055</article-id><article-id pub-id-type="doi">10.1002/ame2.12548</article-id><article-id pub-id-type="publisher-id">AME212548</article-id><article-id pub-id-type="other">AMEM-2024-0359.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Regular Article</subject><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Animal models of cisplatin&#8208;induced neuropathic pain</article-title><alt-title alt-title-type="left-running-head">Li et&#160;al.</alt-title></title-group><contrib-group><contrib id="ame212548-cr-0001" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="N">Ningxin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-4012-787X</contrib-id><xref rid="ame212548-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212548-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="M">Mingzhu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-5682-3405</contrib-id><xref rid="ame212548-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>limingzhu@cancerhosp-ln-cmu.com</email></address></contrib><contrib id="ame212548-cr-0003" contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="S">Shengbo</given-names></name><xref rid="ame212548-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ame212548-cr-0004" contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="J">Jun</given-names></name><xref rid="ame212548-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ame212548-cr-0005" contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="H">Hongzhe</given-names></name><xref rid="ame212548-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212548-cr-0006" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenping</given-names></name><xref rid="ame212548-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ame212548-cr-0007" contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="S">Siyao</given-names></name><xref rid="ame212548-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ame212548-cr-0008" contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="Y">Yuxin</given-names></name><xref rid="ame212548-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ame212548-cr-0009" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Q">Qian</given-names></name><xref rid="ame212548-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ame212548-cr-0010" contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="H">Huini</given-names></name><xref rid="ame212548-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ame212548-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>China Medical University</institution>
<city>Shenyang</city>
<country country="CN">China</country>
</aff><aff id="ame212548-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Cancer Hospital of China Medical University, Liaoning Cancer Hospital &amp; Institute</institution>
<city>Sheng Yang</city>
<country country="CN">China</country>
</aff><aff id="ame212548-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Liaoning University of Traditional Chinese Medicine</institution>
<city>Shenyang</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mingzhu Li, Cancer Hospital of China Medical University, Shenyang, Liaoning 110042, China.<break/>
Email: <email>limingzhu@cancerhosp-ln-cmu.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>8</volume><issue seq="70">7</issue><issue-id pub-id-type="pmc-issue-id">496817</issue-id><issue-id pub-id-type="doi">10.1002/ame2.v8.7</issue-id><issue-title content-type="special-issue-title">Themed Issue: Mechanism Verification of Plant Bioactive Components</issue-title><fpage>1206</fpage><lpage>1214</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Animal Models and Experimental Medicine</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AME2-8-1206.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:AME2-8-1206.pdf"/><abstract><title>Abstract</title><p>Cisplatin chemotherapy has been used as the main treatment for different types of cancer. However, cisplatin chemotherapy&#8208;induced peripheral neuropathic pain (CIPNP) seriously affects the treatment process and quality of life of patients. In addition, it impacts the underlying mechanism and prevention and treatment strategies, indicating that drug selection and efficacy evaluation need to be further investigated. Furthermore, an animal model that is more consistent with the pathological mechanism needs to be developed. In this study, we describe and discuss the methods of developing and detecting CIPNP models in rats and mice induced by cisplatin chemotherapy. The aim was to improve the modeling rate and develop animal models that are more consistent with the developmental pattern of the disease. In addition, the study provides ideal reference animal models for clinical research and drug discovery and development.</p></abstract><abstract abstract-type="graphical"><p>This article illustrates the modeling process of a cisplatin&#8208;induced neuropathic pain model in rats or mice. Multiple modeling tests are required for rats or mice before, during, and after modeling. The appropriate injection method, dose, and modeling method are selected, and multiple assays are chosen for evaluation and comparison.<boxed-text position="anchor" content-type="graphic" id="ame212548-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="AME2-8-1206-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ame212548-kwd-0001">animal models</kwd><kwd id="ame212548-kwd-0002">chemotherapy</kwd><kwd id="ame212548-kwd-0003">cisplatin</kwd><kwd id="ame212548-kwd-0004">peripheral neuropathic pain</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Liaoning Provincial Key Research and Development Program</institution><institution-id institution-id-type="doi">10.13039/501100019033</institution-id></institution-wrap></funding-source><award-id>2024JH2/102500062</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>China Health Promotion Foundation Spark Program</institution></institution-wrap></funding-source><award-id>XH&#8208;D001</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82104838</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="9"/><word-count count="6700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:12.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="AME212548-cit-2001"><string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>S</given-names></string-name>, et al. <article-title>Animal models of cisplatin&#8208;induced neuropathic pain</article-title>. <source>Anim Models Exp Med</source>. <year>2025</year>;<volume>8</volume>:<fpage>1206</fpage>&#8208;<lpage>1214</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ame2.12548</pub-id><pub-id pub-id-type="pmcid">PMC12431596</pub-id><pub-id pub-id-type="pmid">39854055</pub-id></mixed-citation>
</p></notes></front><body id="ame212548-body-0001"><sec id="ame212548-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Cisplatin is a first&#8208;line cytotoxic antitumor drug used to treat different types of solid tumors, such as small&#8208;cell and non&#8208;small&#8208;cell lung cancer, bladder cancer, and testicular cancer. However, more than a quarter of patients on this therapy experience neuropathic pain, primary clinical manifestations such as tingling, burning, sensation or numbness in the hands and feet, and diminished sense of touch. Moreover, the therapy has to be terminated in severe cases.<xref rid="ame212548-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The American Society of Clinical Oncology (ASCO) recommends the use of antidepressants, analgesics, neuroprotective drugs, antiepileptics, or hypothermic hand and foot sleeves/compression gloves for treatment in the Guidelines for the Prevention and Management of Chemotherapy&#8208;Induced Peripheral Neuropathy in Adult Cancer Survivors.<xref rid="ame212548-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> However, all these are only symptomatic in nature. In addition, their efficacy is poor, and the adverse effects of long&#8208;term application are large. In contrast, Chinese medicines have significant efficacy in preventing and treating cisplatin chemotherapy&#8208;induced peripheral neuropathic pain (CIPNP) and can improve the quality of life of patients after chemotherapy. Therefore, it is essential to develop ideal rat and mouse models of CIPNP and elucidate specific modeling detection methods, which can promote the prevention and treatment of CIPNP, the research and development of new drugs, and the improvement in patients' quality of life after chemotherapy. In this paper, we describe the modeling methods and modeling assays of CIPNP models in rats and mice. The aim was to improve the modeling rate, develop animal models that are more in line with the pathological mechanisms, and provide important references for further experimental and clinical studies.</p></sec><sec id="ame212548-sec-0002"><label>2</label><title>ANIMAL SELECTION AND MODEL DEVELOPMENT METHOD</title><p>The effect of pain on rodents is remarkable. The rat and mouse CIPNP models are advantageous due to the ease of simulating injuries and performing operations, and a high rate of modeling; these have emerged as the preferred CIPNP models for researchers. The commonly used dose and regimen of cisplatin in clinics is 40&#8211;120&#8201;mg/m<sup>2</sup>, day 1, repeated every 3&#8201;weeks; or 15&#8211;20&#8201;mg/m<sup>2</sup>, days 1&#8211;5, repeated every 3&#8211;4&#8201;weeks. The neurotoxicity of cisplatin is dose dependent, with symptoms usually appearing in patients receiving cumulative doses of up to 250&#8211;500&#8201;mg/m<sup>2</sup> and partially resolving in most patients after discontinuation of the drug.<xref rid="ame212548-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Therefore, CIPNP models in rats and mice are largely chronic models, and the injection modes are usually intraperitoneal injection and tail vein injection, which are relatively simple, easy to perform, and safe. However, currently, the development of CIPNP models in rats and mice is based on intraperitoneal injection, and the primary adverse reactions caused by intraperitoneal injection are peritoneal swelling and the production of ascites<xref rid="ame212548-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> (Table&#160;<xref rid="ame212548-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="ame212548-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>CIPNP model injection method of rat and mice.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Injection methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Configuration concentration</th><th align="left" valign="bottom" rowspan="1" colspan="1">Dosage mg/(kg&#183;day)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Solvent</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="7" valign="top" colspan="1">i.p.<xref rid="ame212548-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ame212548-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="ame212548-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="ame212548-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="ame212548-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame212548-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="ame212548-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="ame212548-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="ame212548-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="ame212548-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="ame212548-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="ame212548-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="ame212548-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="ame212548-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="ame212548-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="ame212548-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="ame212548-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="ame212548-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="ame212548-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="ame212548-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="ame212548-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="ame212548-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="ame212548-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="ame212548-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="ame212548-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="ame212548-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="ame212548-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="ame212548-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="ame212548-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="ame212548-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="ame212548-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="ame212548-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="ame212548-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="ame212548-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="ame212548-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="ame212548-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="ame212548-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="ame212548-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">Normal saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.08&#8211;0.15&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Normal saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">Normal saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.2&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0.4% Dimethyl sulfoxide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0.4% Dimethyl sulfoxide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.2&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Phosphate buffered saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.23&#8201;mg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">2.3</td><td align="left" valign="top" rowspan="1" colspan="1">Phosphate buffered saline</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">i.v.<xref rid="ame212548-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="ame212548-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Not mentioned</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Normal saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not mentioned</td><td align="left" valign="top" rowspan="1" colspan="1">2.3</td><td align="left" valign="top" rowspan="1" colspan="1">Normal saline</td></tr></tbody></table><table-wrap-foot id="ame212548-ntgp-0001"><fn id="ame212548-note-0001"><p>Abbreviations: CIPNP, chemotherapy&#8208;induced peripheral neuropathic pain; i.p., intraperitoneal injection; i.v., intravenous injection.</p></fn></table-wrap-foot></table-wrap><sec id="ame212548-sec-0003"><label>2.1</label><title>Development of rat model</title><p>Researchers mostly simulate clinical multiple chemotherapies, selecting 2&#8201;mg/kg injected once or twice a week or 3&#8201;mg/kg injected once a week for 4&#8211;5&#8201;weeks to develop a chronic model of CIPNP<xref rid="ame212548-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="ame212548-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="ame212548-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="ame212548-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame212548-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="ame212548-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="ame212548-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="ame212548-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="ame212548-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="ame212548-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="ame212548-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> (Table&#160;<xref rid="ame212548-tbl-0002" ref-type="table">2</xref>). When a single dose of 2&#8201;mg/kg of cisplatin was injected, with a cumulative dose of 6&#8201;mg/kg, and the total dose injected in humans was 37.8&#8201;mg/kg according to the formula for converting drug doses between humans and animals, rats demonstrated abnormal mechanical nociception manifestations. When the single injection dose of cisplatin was 2&#8201;mg/kg, the cumulative dose was 12&#8201;mg/kg, and the total injected dose in the human body was 75.6&#8201;mg/kg (based on the formula of drug dose conversion between humans and animals), rats exhibited nociceptive hypersensitivity.<xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Mechanical pain threshold test; mechanical nociceptive hypersensitivity, hot nociceptive hypersensitivity, and cold nociceptive hypersensitivity experiments; and motor deficit tests can be used to assess the pain behavioral changes in rats and determine the successful development of the cancer pain model.<xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Sprague&#8211;Dawley (SD) and Wistar rats are mostly selected; certain researchers have reported gender differences in the performance of rats to CIPNP, with males exhibiting more pronounced weight loss, longer latency of paw&#8208;shrinking response, and slower motor nerve conduction, whereas females are more pronounced to certain specific histological changes.<xref rid="ame212548-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p><table-wrap position="float" id="ame212548-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>CIPNP model of rats.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Modeling methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Injection methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Accumulated drug dosage (mg/kg)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Pain behavior manifestation</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rat species</th><th align="left" valign="bottom" rowspan="1" colspan="1">Safety</th><th align="left" valign="bottom" rowspan="1" colspan="1">Applicable research areas</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.1&#8201;mg/kg, injected every 3&#8201;days for 15&#8201;days<xref rid="ame212548-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar female rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.1, 0.5, 1&#8201;mg/kg, injected once a day, thrice in total<xref rid="ame212548-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">0.3, 1.5, 3</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MH</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1, 2&#8201;mg/kg, injected once a week for 5&#8201;weeks<xref rid="ame212548-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">5, 10</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Clearly documents that no rat deaths are recorded</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. 1&#8201;mg/kg, injected once a week for 5&#8201;weeks<xref rid="ame212548-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p>
<p>B. 2&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. 5</p>
<p>B. 8</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">+MA, &#8211;HH</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once<xref rid="ame212548-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MH, &#8211;CA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once a day, four times in total<xref rid="ame212548-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once a day, four times in total<xref rid="ame212548-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once every other day, four times in total<xref rid="ame212548-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected twice a week for 4&#8201;weeks<xref rid="ame212548-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MA, +CA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected twice a week for 4.5&#8201;weeks<xref rid="ame212548-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">+CA, +HHO, +MA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Clearly documents that no rat deaths are recorded</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected twice a week for 5&#8201;weeks<xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MA, +CA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 3&#8201;weeks<xref rid="ame212548-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">+CA, +MA, &#8211;HH</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO, +MA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO, +MA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">+CA, +HHO</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Clearly documents that no rat deaths are recorded</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 5&#8201;weeks<xref rid="ame212548-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO, +MA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">SD male and female rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 5&#8201;weeks<xref rid="ame212548-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. 3&#8201;mg/kg, injected once a week for 5&#8201;weeks<xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p>
<p>B. 2&#8201;mg/kg, injected twice a week for 5&#8201;weeks<xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p>
<p>C. 1&#8201;mg/kg, injected thrice a week for 5&#8201;weeks<xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. 15</p>
<p>B. 20</p>
<p>C. 15</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">+CA, +HH, +MA, &#8722;motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">SD male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Three rats in the 2&#8208;mg/kg group died after 3, 10, and 15&#8201;days, respectively. One rat in the 3&#8208;mg/kg group died 10&#8201;days after the last injection</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected twice a week<xref rid="ame212548-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO, &#8722;motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">DA female rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7&#8201;mg/kg, injected once<xref rid="ame212548-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">+HHO</td><td align="left" valign="top" rowspan="1" colspan="1">Wistar male rats</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr></tbody></table><table-wrap-foot id="ame212548-ntgp-0002"><fn id="ame212548-note-0002"><p>Abbreviations: &#8722;, this behavior is not significant after evaluation of cisplatin administration; +, this behavior was significantly evaluated after cisplatin administration; CA, cold allodynia; CIPNP, chemotherapy&#8208;induced peripheral neuropathic pain; DA, Dark Agouti rats; HH, heat hyperalgesia; HHO, heat hypoalgesia; i.p., intraperitoneal injection; i.v., intravenous injection; MA, mechanical allodynia; MH, mechanical hyperalgesia; SD, Sprague&#8211;Dawley.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ame212548-sec-0004"><label>2.2</label><title>Development of the mouse model</title><p>Researchers mostly use the modeling method of intraperitoneal injection of a single dose of 2.3&#8201;mg/kg once a day for 5&#8201;days, with 5&#8201;days of rest for 2&#8201;weeks<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="ame212548-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="ame212548-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="ame212548-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> (Table&#160;<xref rid="ame212548-tbl-0003" ref-type="table">3</xref>). When a single injection dose of 2.3&#8201;mg/kg and the total dose of 6.9&#8201;mg/kg (according to the formula of drug dose conversion between humans and animals) of cisplatin was administered, which was converted to the total injection dose of 60.4&#8201;mg/kg in humans, the mechanical withdrawal reflex threshold (MWT) of mice was significantly reduced.<xref rid="ame212548-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> C57BL/6J mice were used, and no significant gender difference was observed in the behavioral performance.</p><table-wrap position="float" id="ame212548-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>CIPNP model of mice.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Modeling methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Injection methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Accumulated drug dosage (mg/kg)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Pain behavior manifestation</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mice species</th><th align="left" valign="bottom" rowspan="1" colspan="1">Safety</th><th align="left" valign="bottom" rowspan="1" colspan="1">Applicable research areas</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1&#8201;mg/kg, injected once a day, seven times in total<xref rid="ame212548-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">+MH, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">C3H/HeJ male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1&#8201;mg/kg, injected once a day, seven times in total<xref rid="ame212548-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">+MA, +HH</td><td align="left" valign="top" rowspan="1" colspan="1">Albino male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once a day, thrice in total<xref rid="ame212548-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">+MA, +sensation deficit</td><td align="left" valign="top" rowspan="1" colspan="1">WT male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected once per day, thrice in total<xref rid="ame212548-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">+MH</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8201;mg/kg, injected on days 0, 2, 4, and 6<xref rid="ame212548-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">+MH</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once every other day, six times in total<xref rid="ame212548-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">13.8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once every other day, six times in total<xref rid="ame212548-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">13.8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once every other day, six times in total<xref rid="ame212548-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">13.8</td><td align="left" valign="top" rowspan="1" colspan="1">+MA, +CA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">Albino male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once a day for 5&#8201;days for 2&#8201;weeks, with a 5&#8208;day break<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MA, +motor deficit, &#8211;CA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">In the fourth week, mice died in the treatment group</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once a day for 5&#8201;days for 2&#8201;weeks, with a 5&#8208;day break<xref rid="ame212548-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once a day for 5&#8201;days for 2&#8201;weeks, with a 5&#8208;day break<xref rid="ame212548-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once a day for 5&#8201;days for 2&#8201;weeks, with a 5&#8208;day break<xref rid="ame212548-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">+MA, +CA, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.3&#8201;mg/kg, injected once a day for 5&#8201;days, with a 9&#8208;day break, repeated twice<xref rid="ame212548-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">+HH</td><td align="left" valign="top" rowspan="1" colspan="1">BALB/c mice, gender not specified</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +motor deficit</td><td align="left" valign="top" rowspan="1" colspan="1">BALB/c male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#8201;mg/kg, injected twice a week for 4&#8201;weeks<xref rid="ame212548-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MA, +CA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#8201;mg/kg, injected twice a week for 4&#8201;weeks<xref rid="ame212548-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J female mice and A/J female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Developmental research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">+HH, +MA</td><td align="left" valign="top" rowspan="1" colspan="1">Albino male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">+CA, +MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J mice, gender not specified</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanism research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8201;mg/kg, injected once a week for 4&#8201;weeks<xref rid="ame212548-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male and female mice</td><td align="left" valign="top" rowspan="1" colspan="1">Clearly documents that no mice deaths are recorded</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8201;mg/kg, injected once a week for 6&#8201;weeks<xref rid="ame212548-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">i.p.</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">+CH, +MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">On the 20th day, 9.09% of the mice died</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. 10&#8201;mg/kg, injected once<xref rid="ame212548-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p>
<p>B. 2.3&#8201;mg/kg, injected once per day for 5&#8201;days for 2&#8201;weeks, with a 5&#8208;day break<xref rid="ame212548-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>A. i.v.</p>
<p>B. i.p.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>A.10</p>
<p>B.23</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">+MA</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL/6J male mice</td><td align="left" valign="top" rowspan="1" colspan="1">Deathless description</td><td align="left" valign="top" rowspan="1" colspan="1">Curative effect research</td></tr></tbody></table><table-wrap-foot id="ame212548-ntgp-0003"><fn id="ame212548-note-0003"><p>Abbreviations: &#8722;, this behavior is not significant after evaluation of cisplatin administration; +, this behavior was significantly evaluated after cisplatin administration; CA, cold allodynia; CH, cold hyperalgesia; CIPNP, chemotherapy&#8208;induced peripheral neuropathic pain; HH, heat hyperalgesia; HHO, heat hypoalgesia; i.p., intraperitoneal injection; i.v., intravenous injection; MA, mechanical allodynia; MH, mechanical hyperalgesia; WT, wild type mice.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="ame212548-sec-0005"><label>3</label><title>MOLDING INSPECTION METHODS</title><p>Symptoms such as abnormal sensation in the hands and feet induced by cisplatin chemotherapy in patients with CIPNP are manifested as poor mental status, slow activity, and loss of appetite in rat and mouse CIPNP models. Continuous cisplatin administration causes fur roughness and emaciation. The successful development of the CIPNP model in rats and mice is assessed by mechanical nociception, hot and cold nociception, and motor deficit tests.</p><sec id="ame212548-sec-0006"><label>3.1</label><title>Mechanical pain threshold testing</title><sec id="ame212548-sec-0007"><label>3.1.1</label><title>Von Frey pain measurement experiment</title><p>Von Frey, also known as ciliated mechanical stimulation needles, is an alternative marker of abnormal pain in peripheral&#8208; and central&#8208;sensitized states. It is the most commonly used method of mode&#8208;forming detection. The skin or mucosal surfaces of animals were stimulated with fine wires of different diameters and stiffness (0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, 15.0, 26.0, 60.0, 100.0, 180.0, and 300.0&#8201;g), and their thresholds for responding to mechanical pain stimuli were measured. The mice were placed on a wire mesh. When mice were calm, a Von Frey filament was applied through the mesh panel to the plantar surface of their hind paws, applying enough force to bend the filament and hold the contact for 1&#8211;2&#8201;s. If the mouse moved, retracted its hind paw, or licked its foot, this was noted as an &#8220;X,&#8221; and the next lowest filament was tested. If no withdrawal response was observed, the next highest filament was evaluated and recorded as &#8220;O.&#8221; The mechanical withdrawal threshold was defined as the smallest specification of filaments eliciting the withdrawal reflex. The mechanical foot&#8208;retraction response threshold, MWT, was recorded.<xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame212548-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The frequency of the defibrillation response of mice was measured (in %).<xref rid="ame212548-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</p></sec><sec id="ame212548-sec-0008"><label>3.1.2</label><title>Dynamic foot tester</title><p>The Ugo Basile Dynamic Plantar Tester was used, and mice were placed on a wire mesh in a transparent plastic box to acclimatize them to the environment until they were no longer exploring. The stimulation device was placed under the mouse's hind paw, and a calibrated wire was placed under the target area of the hind paw. If the start button is pressed, the device will automatically lift the wire to contact the mouse's hind paw and apply a continuous vertical force of 0&#8211;5&#8201;g at 10&#8208;s intervals until the mouse's hind paw retracted to trigger a stop signal. The instrument automatically recorded the weight intensity threshold that triggered paw retraction.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec><sec id="ame212548-sec-0009"><label>3.1.3</label><title>Randall&#8211;Selitto test</title><p>The Randall&#8211;Selitto test was conducted in a quiet, temperature&#8208;controlled room at 20&#8211;22&#176;C from 10:00&#8201;a.m. to 4:00&#8201;p.m. The rats were acclimatized to the environment by having them climb a cylindrical restrainer with an angled vent on the side of the hind leg for 10&#8211;15&#8201;min. The instantaneous maximum pressure (in grams) during the leg&#8208;retracting response was read using a Basile Algesy meter as the threshold of an injurious sensation. It was measured using a hand&#8208;held instrument; the pressure was increased until the rat underwent withdrawal or vocalization. Measurements were recorded at 5&#8208;min intervals, and the average of three measurements was defined as the paw pressure pain threshold.<xref rid="ame212548-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</p></sec></sec><sec id="ame212548-sec-0010"><label>3.2</label><title>Cold nociceptive hypersensitivity test</title><sec id="ame212548-sec-0011"><label>3.2.1</label><title>Acetone test</title><p>Rats were placed in individual plastic cages on an overhead wire mesh and allowed to acclimatize for at least 15&#8201;min until exploratory behavior was no longer observed. Acetone was filled in a 1&#8208;mL syringe without a needle tip. Air bubbles were removed from the syringe before using acetone. A drop of acetone (~20&#8201;&#956;L) was applied to the plantar surface of the rat's hind paw through a wire mesh, avoiding contact between the syringe and the paw. And the time of the rat's paw&#8208;retraction reaction was recorded for 60&#8201;s after acetone application. The paw&#8208;retraction reaction was manifested as rapid paw fluttering, trembling, paw biting, or paw licking. Paws were evaluated alternately left and right until five measurements were obtained for each paw, with an interval of ~3&#8201;min between the left&#8208; and right&#8208;paw tests. Cold anomalous pain tests were performed on days 0, 4, 8, 12, and 16.<xref rid="ame212548-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="ame212548-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="ame212548-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p></sec><sec id="ame212548-sec-0012"><label>3.2.2</label><title>Cold water bath rat tail withdrawal method</title><p>The rat's tail was placed in a 10&#176;C water bath; the time the tail was immersed in the cold water bath was recorded, with an interval of 5&#8201;min between each measurement. The average of three measurements was taken, with a cutoff time of 15&#8201;s.<xref rid="ame212548-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</p></sec><sec id="ame212548-sec-0013"><label>3.2.3</label><title>Cold plate method</title><p>The cold plate device consists of a transparent glass cylinder and a cold plate. The temperature of the metal plate was set to &#8722;5 to 4&#176;C, and mice were placed in the test area for at least 30&#8211;60&#8201;min for acclimatization. The reaction time of mice to cold stimuli, such as paw licking and jumping, was observed to assess the sensitivity of mice to cold nociception.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec></sec><sec id="ame212548-sec-0014"><label>3.3</label><title>Thermal nociceptive hypersensitivity testing</title><sec id="ame212548-sec-0015"><label>3.3.1</label><title>Thermal radiation method</title><sec id="ame212548-sec-0016"><title>Hargreaves test</title><p>The rat was placed in an 18&#8201;&#215;&#8201;8&#8201;&#215;&#8201;8&#8208;cm transparent plastic box with a piece of glass at the bottom that could transmit infrared rays. After the rats had adapted to the environment for 30&#8211;60&#8201;min, 50&#8201;W of radiant heat was projected through an elliptical aperture onto the heel of the rat's hind paw. The beam was automatically switched off when the rat lifted its paw. The time from the emission of the thermal stimulus to the time when the mouse lifted or licked the hind paw, that is, thermal stimulus response latency, was observed and recorded. Each hind paw was measured thrice, each stimulus interval was 5&#8201;min, and the average of the three measurements was taken.<xref rid="ame212548-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="ame212548-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</p></sec><sec id="ame212548-sec-0017"><title>Thermal radiation tail&#8208;flick method</title><p>In this method, radiation was applied to the distal one third of the rat's tail using an 8&#8201;V/50&#8201;W&#8208;radiation tail&#8208;flick device (tail&#8208;flick device, May Tic., Ankara, Turkey). The thermal stimulus was interrupted when the tail moved, and the latency of the tail flick was recorded. The cutoff time was set to 10&#8201;s to prevent tissue damage to the tail by thermal radiation.<xref rid="ame212548-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p></sec></sec><sec id="ame212548-sec-0018"><label>3.3.2</label><title>Hot plate test method</title><p>Mice were placed in the test area and adapted to the environment for 30&#8211;60&#8201;min. The temperature of the hot plate tester (Columbus) was set to 55&#176;C to measure the latency of the hot plate response for 60&#8201;min before and after the administration of the drug to mice. The cutoff time was set to 30&#8201;s to avoid tissue damage to mice.<xref rid="ame212548-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p></sec><sec id="ame212548-sec-0019"><label>3.3.3</label><title>Hot water bath mouse tail immersion experiment</title><p>Each mouse was wrapped in a wet paper towel, except for the tail, three to four times, each time lasting 1&#8201;min. Then, one third of the distal end of the mouse tail was immersed in a water bath after the mice had adapted to the test environment. The temperature of the water bath was preset at 50.5C&#8201;&#177;&#8201;0.5&#176;C, and the cutoff time was set to 20&#8201;s. The next immersion was performed when the tails of mice were relaxed. The test was restarted if the mice were agitated. The latency of violent tail flicking was recorded, with an interval of at least 30&#8201;min between each time, and the average of three measurements was taken.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec></sec><sec id="ame212548-sec-0020"><label>3.4</label><title>Motor function tests</title><sec id="ame212548-sec-0021"><label>3.4.1</label><title>Rotary rod test</title><p>The rotarod test is a method to assess the motor function of rats for motor coordination and balance. The mice were placed on an accelerated rotating rod, whose speed was increased from 4 to 40&#8201;rpm in 300&#8201;s. A stopwatch was used to record the endurance latency of mice to fall from the rotating rod. Mice were acclimatized for 4&#8201;days before the experiment, with 70&#8201;s per session on day 1, gradually increasing to 300&#8201;s per session on day 4. In case of any premature falls during training, mice were gently returned to the rotating bar. On day 4, the mice were divided into different groups (<italic toggle="yes">n</italic>&#8201;=&#8201;8 per group), and the time of dropping the rod and the speed of the rotating rod at the time of dropping were recorded. The average time on the rotating rod before and after drug administration was calculated to assess their motor coordination and balance ability.<xref rid="ame212548-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Better balance and coordination of mouse limbs resulted in their longer stay on the rotarod, whereas worse balance and coordination resulted in shorter durations.<xref rid="ame212548-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p></sec><sec id="ame212548-sec-0022"><label>3.4.2</label><title>Adhesive removal test</title><p>The adhesive removal test was used to assess murine sensorimotor dysfunction and motor asymmetry. We placed the mice in a 10&#8201;&#215;&#8201;20&#8201;&#215;&#8201;10&#8208;cm transparent plastic box, after which two similar tapes were applied to the hairless portion of each of their front paws using the same pressure. The time between the first contact with the tape and the complete removal of the tape was recorded.<xref rid="ame212548-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p></sec><sec id="ame212548-sec-0023"><label>3.4.3</label><title>Grip strength test</title><p>A grip strength meter (Stoelting Wood Dale, IL), consisting of a force sensor with a digital display and a metal plate with a hanger, was used. Each mouse was placed on the Stoelting Wood Dale plate. The mouse grasped the probe firmly with its forelimbs, and its tail was pulled with a gradually increasing force until it could not grasp the hanger. Ensuring that the mouse grasped the top of the grid and the trunk remained horizontal, the maximum grip strength value of the mouse displayed on the screen was recorded and averaged thrice.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec></sec></sec><sec sec-type="discussion" id="ame212548-sec-0024"><label>4</label><title>DISCUSSION</title><p>The latest statistics from the International Agency for Research on Cancer estimated nearly 20 million new cancer cases in 2022, with lung cancer as the most common cancer (200&#8201;000 new cases) accounting for 12.4% of the new cancer cases worldwide.<xref rid="ame212548-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> The National Comprehensive Cancer Network in its 2024 guidelines for non&#8208;small&#8208;cell lung cancer included ositinib + pemetrexed + cisplatin or carboplatin as the first&#8208;line treatment regimen for nonsquamous cell carcinoma. Initially four cycles of systemic therapy with cisplatin are recommended, and continuation for six cycles may be considered if the patient tolerates the treatment well.<xref rid="ame212548-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> It has been reported that 30%&#8211;40% of patients treated with cisplatin develop distal limb pain and sensory abnormalities, which can progress to severe neuropathic pain and sensory ataxia in advanced stages.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Furthermore, 47% of patients continue to have symptoms of CIPNP at 6&#8201;years after the end of chemotherapy and even throughout life. The mechanism of CIPNP is intricate. Studies have demonstrated that it is intricately related to chemotherapeutic drug&#8211;induced intraepidermal nerve fiber damage, ion channel dysregulation, cytokine upregulation, and immune activation of the nervous system.<xref rid="ame212548-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> No drugs with preventive and curative effects are available, and the 2014 ASCO guidelines recommend duloxetine analgesic treatment for severe pain. Moreover, we lack established diagnostic criteria for CIPNP, and more clinical trials and animal studies are urgently required to address this major clinical problem with regard to the preventive and curative drugs for different types of chemotherapeutic agents and their induced CIPNP.</p><p>Researchers generally select mechanical nociception, cold nociception, and hot nociception experiments to determine whether the cancer pain model is successful; however, the detection standard of pain behavior tests is still controversial. Among them, the mechanical pain test is the most commonly used modeling test, and the Von Frey method is regarded as the &#8220;gold standard&#8221; of mechanical pain tests because of its classical, simple, and efficient nature. However, it has disadvantages such as low accuracy and poor reproducibility. Therefore, researchers have recently used electronic mechanical pain testers to improve their accuracy.<xref rid="ame212548-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Cold pain threshold and heat pain threshold detection are also commonly used for mold&#8208;forming detection; researchers mostly use hot and cold plate pain testers for assessment, which has the advantages of precise temperature control, rapid cooling, and prevention of scalded animals. The CIPNP model is mostly used in three types of medical research: mechanism research, efficacy research, and developmental research. Mechanistic research refers to the study of the pathogenesis of cisplatin&#8208;induced CIPNP and the mechanism of drug action in animal models and their pathological mechanisms. In the CIPNP mechanism study model, one to two kinds of behavioral tests are evaluated using SD rats (1&#8211;2&#8201;mg/kg, injected twice a week for 5&#8201;weeks) or C57BL/6J mice (2.3&#8201;mg/kg, injected once a day for 5&#8201;days, resting for 5&#8201;days, for 2&#8201;weeks).<xref rid="ame212548-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame212548-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Efficacy studies are primarily used to evaluate the effectiveness of a drug or compound in treating CIPNP. The accuracy and reliability of animal model experiments are crucial to the efficacious evaluation and success of the drug development process. In the efficacy study model, multiple pain behavior detection criteria should be selected to obtain a comprehensive assessment, and a scientifically rich animal model evaluation system should be used. SD rats (3&#8201;mg/kg, injected once a week for 4&#8201;weeks) or C57BL/6J mice (2.3&#8201;mg/kg, injected once a day for 5&#8201;days, with 5&#8201;days of rest for 2&#8201;weeks; or a high dose of 5&#8201;mg/kg, injected once a week for 4&#8201;weeks) can be selected.<xref rid="ame212548-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="ame212548-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="ame212548-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="ame212548-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="ame212548-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="ame212548-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Developmental studies are based on the results of applied research and current science and technology to promote the development of CIPNP research. Developmental studies can select SD rats (2&#8201;mg/kg, injected twice a week for 5&#8201;weeks) or C57BL/6J mice (2.3&#8201;mg/kg, injected every day for six times of modeling).<xref rid="ame212548-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="ame212548-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Limitations of animal model experiments should be acknowledged. These include species differences between animals and humans, and the experimental results may be affected by several factors. It is necessary to fully consider the limitations and implement the corresponding measures to reduce the error and improve the accuracy of the experiment when conducting animal model experiments. Domestic and foreign researchers have observed the model formation test for no more than 2&#8201;weeks (14&#8201;days), and the time point of the behavioral test is primarily every 5&#8201;days or once a week; however, certain studies found that the animals exhibited nociceptive allergy at the beginning of the first week and severe nociceptive allergy during the second and third weeks.<xref rid="ame212548-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Therefore, it is recommended that researchers increase the observation time of behavioral tests to better develop a high&#8208;quality model.</p><p>The 2014 ASCO guidelines recommend only duloxetine as a first&#8208;line agent for the treatment of CIPNP, whereas the German Society of Neurology guidelines recommend capsaicin patches as a second&#8208;line agent for treating any kind of neuropathic pain.<xref rid="ame212548-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="ame212548-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> However, the treatment of CIPNP is not yet supported by high&#8208;quality studies and lacks validation in randomized clinical trials. In this regard, the application of rat and mouse models of CIPNP can promote research on the pathogenesis and prevention strategies of CIPNP, and thereby improve the quality of life of patients and their adherence to treatment regimens.</p></sec><sec id="ame212548-sec-0032"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Ningxin Li:</bold> Conceptualization; methodology; writing &#8211; original draft. <bold>Mingzhu Li:</bold> Funding acquisition; supervision; writing &#8211; review and editing. <bold>Shengbo Jin:</bold> Resources; validation; visualization. <bold>Jun Yu:</bold> Conceptualization; investigation; methodology. <bold>Hongzhe Wei:</bold> Data curation; validation. <bold>Wenping Wang:</bold> Conceptualization; supervision; validation. <bold>Siyao Ma:</bold> Investigation. <bold>Yuxin Jiang:</bold> Formal analysis; software. <bold>Qian Liu:</bold> Methodology. <bold>Huini Yao:</bold> Conceptualization.</p></sec><sec id="ame212548-sec-0025"><title>FUNDING INFORMATION</title><p>This study was funded by the National Natural Science Foundation of China (grant number 82104838), the China Health Promotion Foundation Spark Program (grant number XH&#8208;D001), and the Liaoning Provincial Key Research and Development Program (grant numbers 2024JH2/102500062).</p></sec><sec sec-type="COI-statement" id="ame212548-sec-0026"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors have no relevant financial or nonfinancial interests to disclose.</p></sec><sec id="ame212548-sec-0029"><title>ETHICS STATEMENT</title><p>This review article was not subject to any ethics approval from the institutions.</p></sec><sec id="ame212548-sec-0030"><title>CONSENT TO PARTICIPATE</title><p>All authors provided their consent to participate.</p></sec><sec id="ame212548-sec-0031"><title>CONSENT FOR PUBLICATION</title><p>All authors gave their consent for publication of this review article.</p></sec></body><back><ack id="ame212548-sec-0220"><title>ACKNOWLEDGMENTS</title><p>We sincerely thank the providers of funds, including: National Natural Science Foundation of China (Grant:82104838), China Health Promotion Foundation Spark Program (Grant:XH&#8208;D001), Liaoning Provincial Key Research and Development Program (Grant:2024JH2/102500062). We appreciate the constructive comments provided by the anonymous reviewers, which greatly improved the quality of this manuscript.</p></ack><sec sec-type="data-availability" id="ame212548-sec-0028"><title>DATA AVAILABILITY STATEMENT</title><p>No data was used for the research described in the article.</p></sec><ref-list content-type="cited-references" id="ame212548-bibl-0001"><title>REFERENCES</title><ref id="ame212548-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ame212548-cit-0001"><string-name name-style="western"><surname>Bagher</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Binmahfouz</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Shaik</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Eid</surname><given-names>BG</given-names></string-name>. <article-title>Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin&#8208;induced neuropathic pain in mice</article-title>. <source>Saudi Pharm J</source>. <year>2023</year>;<volume>31</volume>(<issue>2</issue>):<fpage>255</fpage>&#8208;<lpage>264</lpage>.<pub-id pub-id-type="pmid">36942271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsps.2022.12.011</pub-id><pub-id pub-id-type="pmcid">PMC10023546</pub-id></mixed-citation></ref><ref id="ame212548-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ame212548-cit-0002"><string-name name-style="western"><surname>Hershman</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dworkin</surname><given-names>RH</given-names></string-name>, et&#160;al. <article-title>Prevention and management of chemotherapy&#8208;induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>18</issue>):<fpage>1941</fpage>&#8208;<lpage>1967</lpage>.<pub-id pub-id-type="pmid">24733808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.54.0914</pub-id></mixed-citation></ref><ref id="ame212548-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ame212548-cit-0003"><string-name name-style="western"><surname>Alberti</surname><given-names>P</given-names></string-name>. <article-title>Platinum&#8208;drugs induced peripheral neurotoxicity: clinical course and preclinical evidence</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2019</year>;<volume>15</volume>(<issue>6</issue>):<fpage>487</fpage>&#8208;<lpage>497</lpage>.<pub-id pub-id-type="pmid">31116618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2019.1622679</pub-id></mixed-citation></ref><ref id="ame212548-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ame212548-cit-0004"><string-name name-style="western"><surname>Al Moundhri</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Salam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Al Mahrouqee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Beegam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>BH</given-names></string-name>. <article-title>The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies</article-title>. <source>J Med Toxicol</source>. <year>2013</year>;<volume>9</volume>(<issue>1</issue>):<fpage>25</fpage>&#8208;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22648527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-012-0239-x</pub-id><pub-id pub-id-type="pmcid">PMC3576489</pub-id></mixed-citation></ref><ref id="ame212548-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ame212548-cit-0005"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, et&#160;al. <article-title>Prostaglandin D2 contributes to cisplatin&#8208;induced neuropathic pain in rats via DP2 receptor in the spinal cord</article-title>. <source>Korean J Pain</source>. <year>2021</year>;<volume>34</volume>(<issue>1</issue>):<fpage>27</fpage>&#8208;<lpage>34</lpage>.<pub-id pub-id-type="pmid">33380565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3344/kjp.2021.34.1.27</pub-id><pub-id pub-id-type="pmcid">PMC7783857</pub-id></mixed-citation></ref><ref id="ame212548-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ame212548-cit-0006"><string-name name-style="western"><surname>Kim</surname><given-names>YO</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>MH</given-names></string-name>. <article-title>Antiallodynic effect of intrathecal Korean red ginseng in cisplatin&#8208;induced neuropathic pain rats</article-title>. <source>Pharmacology</source>. <year>2020</year>;<volume>105</volume>(<issue>3&#8211;4</issue>):<fpage>173</fpage>&#8208;<lpage>180</lpage>.<pub-id pub-id-type="pmid">31578020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000503259</pub-id></mixed-citation></ref><ref id="ame212548-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ame212548-cit-0007"><string-name name-style="western"><surname>Lee</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>KH</given-names></string-name>. <article-title>ANTI&#8208;NOCICEPTIVE EFFECT OF AGRIMONIA EUPATORIA EXTRACT ON A CISPLATIN&#8208;INDUCED NEUROPATHIC MODEL</article-title>. <source>Afr J Tradit Complement Altern Med</source>. <year>2016</year>;<volume>13</volume>(<issue>5</issue>):<fpage>139</fpage>&#8208;<lpage>144</lpage>.<pub-id pub-id-type="pmid">28487904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21010/ajtcam.v13i5.18</pub-id><pub-id pub-id-type="pmcid">PMC5416632</pub-id></mixed-citation></ref><ref id="ame212548-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ame212548-cit-0008"><string-name name-style="western"><surname>Kuai</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Ju</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>F</given-names></string-name>. <article-title>Corydalis saxicola alkaloids attenuate cisplatin&#8208;induced neuropathic pain by reducing loss of IENF and blocking TRPV1 activation</article-title>. <source>Am J Chin Med</source>. <year>2020</year>;<volume>48</volume>(<issue>2</issue>):<fpage>407</fpage>&#8208;<lpage>428</lpage>.<pub-id pub-id-type="pmid">32138533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X20500214</pub-id></mixed-citation></ref><ref id="ame212548-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ame212548-cit-0009"><string-name name-style="western"><surname>Guindon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Takacs</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bradshaw</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Hohmann</surname><given-names>AG</given-names></string-name>. <article-title>Alterations in endocannabinoid tone following chemotherapy&#8208;induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty&#8208;acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment</article-title>. <source>Pharmacol Res</source>. <year>2013</year>;<volume>67</volume>(<issue>1</issue>):<fpage>94</fpage>&#8208;<lpage>109</lpage>.<pub-id pub-id-type="pmid">23127915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2012.10.013</pub-id><pub-id pub-id-type="pmcid">PMC3525790</pub-id></mixed-citation></ref><ref id="ame212548-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ame212548-cit-0010"><string-name name-style="western"><surname>Shahid</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Subhan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sewell</surname><given-names>RDE</given-names></string-name>. <article-title>Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy&#8208;induced peripheral neuropathy</article-title>. <source>BMC Pharmacol Toxicol</source>. <year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>51</fpage>.<pub-id pub-id-type="pmid">31462283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40360-019-0329-3</pub-id><pub-id pub-id-type="pmcid">PMC6714310</pub-id></mixed-citation></ref><ref id="ame212548-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ame212548-cit-0011"><string-name name-style="western"><surname>Akbar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Subhan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shahid</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>6&#8208;Methoxyflavanone abates cisplatin&#8208;induced neuropathic pain apropos anti&#8208;inflammatory mechanisms: a behavioral and molecular simulation study</article-title>. <source>Eur J Pharmacol</source>. <year>2020</year>;<volume>5</volume>(<issue>872</issue>):<elocation-id>172972</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2020.172972</pub-id><pub-id pub-id-type="pmid">32006559</pub-id></mixed-citation></ref><ref id="ame212548-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ame212548-cit-0012"><string-name name-style="western"><surname>Shahid</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Subhan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sewell</surname><given-names>RDE</given-names></string-name>. <article-title>The flavonoid 6&#8208;methoxyflavone allays cisplatin&#8208;induced neuropathic allodynia and hypoalgesia</article-title>. <source>Biomed Pharmacother</source>. <year>2017</year>;<volume>95</volume>:<fpage>1725</fpage>&#8208;<lpage>1733</lpage>.<pub-id pub-id-type="pmid">28962077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.09.108</pub-id></mixed-citation></ref><ref id="ame212548-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ame212548-cit-0013"><string-name name-style="western"><surname>Moetamani&#8208;Ahmadi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mahmoud Ahmadzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alaei</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Pegylated nanoliposomal cisplatin ameliorates chemotherapy&#8208;induced peripheral neuropathy</article-title>. <source>Int J Pharm</source>. <year>2024</year>;<volume>5</volume>(<issue>652</issue>):<elocation-id>123839</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2024.123839</pub-id><pub-id pub-id-type="pmid">38266944</pub-id></mixed-citation></ref><ref id="ame212548-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ame212548-cit-0014"><string-name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Subhan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>NU</given-names></string-name>, <string-name name-style="western"><surname>Shahid</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>FU</given-names></string-name>, <string-name name-style="western"><surname>Sewell</surname><given-names>RDE</given-names></string-name>. <article-title>Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin&#8208;induced neuropathic pain model</article-title>. <source>Eur J Pharmacol</source>. <year>2017</year>;<volume>5</volume>(<issue>814</issue>):<fpage>302</fpage>&#8208;<lpage>312</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2017.08.040</pub-id><pub-id pub-id-type="pmid">28865678</pub-id></mixed-citation></ref><ref id="ame212548-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ame212548-cit-0015"><string-name name-style="western"><surname>Bilir&#8208;Yildiz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sunay</surname><given-names>FB</given-names></string-name>, <string-name name-style="western"><surname>Yilmaz</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Bozkurt&#8208;Girit</surname><given-names>O</given-names></string-name>. <article-title>Low&#8208;intensity low&#8208;frequency pulsed ultrasound ameliorates sciatic nerve dysfunction in a rat model of cisplatin&#8208;induced peripheral neuropathy</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>7</issue>):<fpage>8125</fpage>.<pub-id pub-id-type="pmid">35581281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-11978-z</pub-id><pub-id pub-id-type="pmcid">PMC9114430</pub-id></mixed-citation></ref><ref id="ame212548-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ame212548-cit-0016"><string-name name-style="western"><surname>Authier</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gillet</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Fialip</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eschalier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Coudore</surname><given-names>F</given-names></string-name>. <article-title>An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections</article-title>. <source>Exp Neurol</source>. <year>2003</year>;<volume>182</volume>(<issue>1</issue>):<fpage>12</fpage>&#8208;<lpage>20</lpage>.<pub-id pub-id-type="pmid">12821373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-4886(03)00003-7</pub-id></mixed-citation></ref><ref id="ame212548-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ame212548-cit-0017"><string-name name-style="western"><surname>Qui&#241;onez&#8208;Bastidas</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Palomino&#8208;Hern&#225;ndez</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez&#8208;Ort&#237;z</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Antiallodynic effect of PhAR&#8208;DBH&#8208;me involves cannabinoid and TRPV1 receptors</article-title>. <source>Pharmacol Res Perspect</source>. <year>2020</year>;<volume>8</volume>(<issue>5</issue>):<elocation-id>e00663</elocation-id>.<pub-id pub-id-type="pmid">32965798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.663</pub-id><pub-id pub-id-type="pmcid">PMC7510332</pub-id></mixed-citation></ref><ref id="ame212548-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ame212548-cit-0018"><string-name name-style="western"><surname>Cata</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Dougherty</surname><given-names>PM</given-names></string-name>. <article-title>Behavioral and electrophysiological studies in rats with cisplatin&#8208;induced chemoneuropathy</article-title>. <source>Brain Res</source>. <year>2008</year>;<volume>16</volume>(<issue>1230</issue>):<fpage>91</fpage>&#8208;<lpage>98</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2008.07.022</pub-id><pub-id pub-id-type="pmcid">PMC2630495</pub-id><pub-id pub-id-type="pmid">18657527</pub-id></mixed-citation></ref><ref id="ame212548-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ame212548-cit-0019"><string-name name-style="western"><surname>Vera</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chiarlone</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cabezos</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Pascual</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Abalo</surname><given-names>R</given-names></string-name>. <article-title>WIN 55,212&#8208;2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat</article-title>. <source>Life Sci</source>. <year>2007</year>;<volume>81</volume>(<issue>6</issue>):<fpage>468</fpage>&#8208;<lpage>479</lpage>.<pub-id pub-id-type="pmid">17673260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2007.06.012</pub-id></mixed-citation></ref><ref id="ame212548-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ame212548-cit-0020"><string-name name-style="western"><surname>Paniagua</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goicoechea</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Abalo</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>May a sigma&#8208;1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats?</article-title><source>Eur J Pain</source>. <year>2019</year>;<volume>23</volume>(<issue>3</issue>):<fpage>603</fpage>&#8208;<lpage>620</lpage>.<pub-id pub-id-type="pmid">30376213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejp.1333</pub-id></mixed-citation></ref><ref id="ame212548-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ame212548-cit-0021"><string-name name-style="western"><surname>Onk</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mammadov</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Suleyman</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>The effect of thiamine and its metabolites on peripheral neuropathic pain induced by cisplatin in rats</article-title>. <source>Exp Anim</source>. <year>2018</year>;<volume>67</volume>(<issue>2</issue>):<fpage>259</fpage>&#8208;<lpage>269</lpage>.<pub-id pub-id-type="pmid">29332858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1538/expanim.17-0090</pub-id><pub-id pub-id-type="pmcid">PMC5955757</pub-id></mixed-citation></ref><ref id="ame212548-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ame212548-cit-0022"><string-name name-style="western"><surname>Boyle</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Beatson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Monk</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Kurek</surname><given-names>JB</given-names></string-name>. <article-title>The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2001</year>;<volume>48</volume>(<issue>6</issue>):<fpage>429</fpage>&#8208;<lpage>434</lpage>.<pub-id pub-id-type="pmid">11800022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-001-0382-6</pub-id></mixed-citation></ref><ref id="ame212548-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ame212548-cit-0023"><string-name name-style="western"><surname>Mahmoud</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Horany</surname><given-names>HEE</given-names></string-name>, <string-name name-style="western"><surname>Aboalsoud</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abd&#8208;Ellatif</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Sheikh</surname><given-names>AAE</given-names></string-name>, <string-name name-style="western"><surname>Aboalsoud</surname><given-names>A</given-names></string-name>. <article-title>Targeting oxidative stress, autophagy, and apoptosis by quercetin to ameliorate cisplatin&#8208;induced peripheral neuropathy in rats</article-title>. <source>J Microsc Ultrastruct</source>. <year>2023</year>;<volume>11</volume>(<issue>2</issue>):<fpage>107</fpage>&#8208;<lpage>114</lpage>.<pub-id pub-id-type="pmid">37448816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/jmau.jmau_78_22</pub-id><pub-id pub-id-type="pmcid">PMC10337675</pub-id></mixed-citation></ref><ref id="ame212548-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ame212548-cit-0024"><string-name name-style="western"><surname>Ta</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Low</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Windebank</surname><given-names>AJ</given-names></string-name>. <article-title>Mice with cisplatin and oxaliplatin&#8208;induced painful neuropathy develop distinct early responses to thermal stimuli</article-title>. <source>Mol Pain</source>. <year>2009</year>;<volume>26</volume>(<issue>5</issue>):<fpage>9</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-8069-5-9</pub-id><pub-id pub-id-type="pmcid">PMC2655284</pub-id><pub-id pub-id-type="pmid">19245717</pub-id></mixed-citation></ref><ref id="ame212548-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ame212548-cit-0025"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Junigan</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Trinh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kavelaars</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heijnen</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Grace</surname><given-names>PM</given-names></string-name>. <article-title>HDAC6 inhibition reverses cisplatin&#8208;induced mechanical hypersensitivity via Tonic Delta opioid receptor signaling</article-title>. <source>J Neurosci</source>. <year>2022</year>;<volume>42</volume>(<issue>42</issue>):<fpage>7862</fpage>&#8208;<lpage>7874</lpage>.<pub-id pub-id-type="pmid">36096670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1182-22.2022</pub-id><pub-id pub-id-type="pmcid">PMC9617617</pub-id></mixed-citation></ref><ref id="ame212548-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ame212548-cit-0026"><string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>XC</given-names></string-name>, et&#160;al. <article-title>Spinal neuronal GRK2 contributes to preventive effect by Electroacupuncture on cisplatin&#8208;induced peripheral neuropathy in mice</article-title>. <source>Anesth Analg</source>. <year>2022</year>;<volume>134</volume>(<issue>1</issue>):<fpage>204</fpage>&#8208;<lpage>215</lpage>.<pub-id pub-id-type="pmid">34652301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000005768</pub-id><pub-id pub-id-type="pmcid">PMC8647702</pub-id></mixed-citation></ref><ref id="ame212548-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ame212548-cit-0027"><string-name name-style="western"><surname>Ruan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Water extract of Notopterygium incisum alleviates cold allodynia in neuropathic pain by regulation of TRPA1</article-title>. <source>J Ethnopharmacol</source>. <year>2023</year>;<volume>6</volume>(<issue>305</issue>):<elocation-id>116065</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2022.116065</pub-id><pub-id pub-id-type="pmid">36587876</pub-id></mixed-citation></ref><ref id="ame212548-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ame212548-cit-0028"><string-name name-style="western"><surname>Becker</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fialho</surname><given-names>MFP</given-names></string-name>, <string-name name-style="western"><surname>Brusco</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>SM</given-names></string-name>. <article-title>Kinin B1 and B2 receptors contribute to cisplatin&#8208;induced painful peripheral neuropathy in male mice</article-title>. <source>Pharmaceutics</source>. <year>2023</year>;<volume>15</volume>(<issue>3</issue>):<fpage>852</fpage>.<pub-id pub-id-type="pmid">36986713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15030852</pub-id><pub-id pub-id-type="pmcid">PMC10051506</pub-id></mixed-citation></ref><ref id="ame212548-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ame212548-cit-0029"><string-name name-style="western"><surname>Cataldo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Erb</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lunzer</surname><given-names>MM</given-names></string-name>, et&#160;al. <article-title>The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin&#8208;evoked neuropathic pain without tolerance or reward</article-title>. <source>Neuropharmacology</source>. <year>2019</year>;<volume>1</volume>(<issue>158</issue>):<elocation-id>107598</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.04.004</pub-id><pub-id pub-id-type="pmcid">PMC6745246</pub-id><pub-id pub-id-type="pmid">30970233</pub-id></mixed-citation></ref><ref id="ame212548-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ame212548-cit-0030"><string-name name-style="western"><surname>Laumet</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Edralin</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Heijnen</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Kavelaars</surname><given-names>A</given-names></string-name>. <article-title>Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy&#8208;induced peripheral neuropathy in mice</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>6</issue>):<fpage>1459</fpage>&#8208;<lpage>1468</lpage>.<pub-id pub-id-type="pmid">30720585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001512</pub-id><pub-id pub-id-type="pmcid">PMC6527475</pub-id></mixed-citation></ref><ref id="ame212548-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ame212548-cit-0031"><string-name name-style="western"><surname>Inyang</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Laumet</surname><given-names>G</given-names></string-name>. <article-title>The &#956;&#8208;&#948; opioid heteromer masks latent pain sensitization in neuropathic and inflammatory pain in male and female mice</article-title>. <source>Brain Res</source>. <year>2021</year>;<volume>1756</volume>(<issue>1</issue>):<elocation-id>147298</elocation-id>.<pub-id pub-id-type="pmid">33516809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2021.147298</pub-id></mixed-citation></ref><ref id="ame212548-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ame212548-cit-0032"><string-name name-style="western"><surname>Shim</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Peripheral and central oxidative stress in chemotherapy&#8208;induced neuropathic pain</article-title>. <source>Mol Pain</source>. <year>2019</year>;<volume>15</volume>:<fpage>98</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1744806919840098</pub-id><pub-id pub-id-type="pmcid">PMC6458664</pub-id><pub-id pub-id-type="pmid">30857460</pub-id></mixed-citation></ref><ref id="ame212548-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ame212548-cit-0033"><string-name name-style="western"><surname>Park</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Stokes</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Pirie</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Skahen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shtaerman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yaksh</surname><given-names>TL</given-names></string-name>. <article-title>Persistent hyperalgesia in the cisplatin&#8208;treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept</article-title>. <source>Anesth Analg</source>. <year>2013</year>;<volume>116</volume>(<issue>1</issue>):<fpage>224</fpage>&#8208;<lpage>231</lpage>.<pub-id pub-id-type="pmid">23223118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e31826e1007</pub-id><pub-id pub-id-type="pmcid">PMC3530135</pub-id></mixed-citation></ref><ref id="ame212548-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ame212548-cit-0034"><string-name name-style="western"><surname>Woller</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Corr</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yaksh</surname><given-names>TL</given-names></string-name>. <article-title>Differences in cisplatin&#8208;induced mechanical allodynia in male and female mice</article-title>. <source>Eur J Pain</source>. <year>2015</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1476</fpage>&#8208;<lpage>1485</lpage>.<pub-id pub-id-type="pmid">25716290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejp.679</pub-id><pub-id pub-id-type="pmcid">PMC4755718</pub-id></mixed-citation></ref><ref id="ame212548-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ame212548-cit-0035"><string-name name-style="western"><surname>Chiou</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>YC</given-names></string-name>, et&#160;al. <article-title>Liu Jun Zi Tang&#8208;a potential, multi&#8208;herbal complementary therapy for chemotherapy&#8208;induced neurotoxicity</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1258</fpage>.<pub-id pub-id-type="pmid">29690597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19041258</pub-id><pub-id pub-id-type="pmcid">PMC5979528</pub-id></mixed-citation></ref><ref id="ame212548-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ame212548-cit-0036"><string-name name-style="western"><surname>Meng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>. <article-title>Berberine alleviate cisplatin&#8208;induced peripheral neuropathy by modulating inflammation signal via TRPV1</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>26</volume>(<issue>12</issue>):<elocation-id>774795</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.774795</pub-id><pub-id pub-id-type="pmcid">PMC8826251</pub-id><pub-id pub-id-type="pmid">35153744</pub-id></mixed-citation></ref><ref id="ame212548-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ame212548-cit-0037"><string-name name-style="western"><surname>Lessans</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lassiter</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Carozzi</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Global transcriptomic profile of dorsal root ganglion and physiological correlates of cisplatin&#8208;induced peripheral neuropathy</article-title>. <source>Nurs Res</source>. <year>2019</year>;<volume>68</volume>:<fpage>145</fpage>&#8208;<lpage>155</lpage>.<pub-id pub-id-type="pmid">30586060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NNR.0000000000000338</pub-id></mixed-citation></ref><ref id="ame212548-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ame212548-cit-0038"><string-name name-style="western"><surname>Akhtar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Naeem</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Faheem</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nadeem</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mehmood</surname><given-names>A</given-names></string-name>. <article-title>Benzimidazole derivative ameliorates opioid&#8208;mediated tolerance during anticancer&#8208; induced neuropathic pain in mice</article-title>. <source>Anticancer Agents Med Chem</source>. <year>2021</year>;<volume>21</volume>(<issue>3</issue>):<fpage>365</fpage>&#8208;<lpage>371</lpage>.<pub-id pub-id-type="pmid">32819235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520620999200818155031</pub-id></mixed-citation></ref><ref id="ame212548-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ame212548-cit-0039"><string-name name-style="western"><surname>Marcus</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Zee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Tolerance to the antinociceptive effects of chronic morphine requires c&#8208;Jun N&#8208;terminal kinase</article-title>. <source>Mol Pain</source>. <year>2015</year>;<volume>12</volume>(<issue>11</issue>):<fpage>34</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12990-015-0031-4</pub-id><pub-id pub-id-type="pmcid">PMC4465461</pub-id><pub-id pub-id-type="pmid">26065412</pub-id></mixed-citation></ref><ref id="ame212548-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ame212548-cit-0040"><string-name name-style="western"><surname>Sepulveda</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Raup&#8208;Konsavage</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vrana</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Graziane</surname><given-names>NM</given-names></string-name>. <article-title>Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy&#8208;induced peripheral neuropathy</article-title>. <source>Eur J Pain</source>. <year>2022</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1950</fpage>&#8208;<lpage>1966</lpage>.<pub-id pub-id-type="pmid">35899583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejp.2016</pub-id></mixed-citation></ref><ref id="ame212548-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="ame212548-cit-0041"><string-name name-style="western"><surname>Nachnani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sepulveda</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Booth</surname><given-names>JL</given-names></string-name>, et&#160;al. <article-title>Chronic Cannabigerol as an effective therapeutic for cisplatin&#8208;induced neuropathic pain</article-title>. <source>Pharmaceuticals (Basel)</source>. <year>2023</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1442</fpage>.<pub-id pub-id-type="pmid">37895913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16101442</pub-id><pub-id pub-id-type="pmcid">PMC10610438</pub-id></mixed-citation></ref><ref id="ame212548-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="ame212548-cit-0042"><string-name name-style="western"><surname>Guindon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wager&#8208;Miller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hohmann</surname><given-names>AG</given-names></string-name>. <article-title>Optimization of a cisplatin model of chemotherapy&#8208;induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status</article-title>. <source>Mol Pain</source>. <year>2014</year>;<volume>4</volume>(<issue>10</issue>):<fpage>56</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-8069-10-56</pub-id><pub-id pub-id-type="pmcid">PMC4247770</pub-id><pub-id pub-id-type="pmid">25189223</pub-id></mixed-citation></ref><ref id="ame212548-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="ame212548-cit-0043"><string-name name-style="western"><surname>Dewaeles</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fellah</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Istradefylline protects from cisplatin&#8208;induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects</article-title>. <source>J Clin Invest</source>. <year>2022</year>;<volume>132</volume>(<issue>22</issue>):<elocation-id>e152924</elocation-id>.<pub-id pub-id-type="pmid">36377661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI152924</pub-id><pub-id pub-id-type="pmcid">PMC9663157</pub-id></mixed-citation></ref><ref id="ame212548-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="ame212548-cit-0044"><string-name name-style="western"><surname>Joseph</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>JD</given-names></string-name>. <article-title>Comparison of oxaliplatin&#8208; and cisplatin&#8208;induced painful peripheral neuropathy in the rat</article-title>. <source>J Pain</source>. <year>2009</year>;<volume>10</volume>(<issue>5</issue>):<fpage>534</fpage>&#8208;<lpage>541</lpage>.<pub-id pub-id-type="pmid">19231296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2008.12.003</pub-id><pub-id pub-id-type="pmcid">PMC2741410</pub-id></mixed-citation></ref><ref id="ame212548-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="ame212548-cit-0045"><string-name name-style="western"><surname>Wongtawatchai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Agthong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaewsema</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chentanez</surname><given-names>V</given-names></string-name>. <article-title>Sex&#8208;related differences in cisplatin&#8208;induced neuropathy in rats</article-title>. <source>J Med Assoc Thai</source>. <year>2009</year>;<volume>92</volume>(<issue>11</issue>):<fpage>1485</fpage>&#8208;<lpage>1491</lpage>.<pub-id pub-id-type="pmid">19938741</pub-id></mixed-citation></ref><ref id="ame212548-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="ame212548-cit-0046"><string-name name-style="western"><surname>Manjavachi</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Passos</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Trevisan</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel&#8208;induced peripheral neuropathy in mice</article-title>. <source>Neuropharmacology</source>. <year>2019</year>;<volume>151</volume>:<fpage>136</fpage>&#8208;<lpage>143</lpage>.<pub-id pub-id-type="pmid">30991054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.04.014</pub-id></mixed-citation></ref><ref id="ame212548-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="ame212548-cit-0047"><string-name name-style="western"><surname>Bray</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sung</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. <year>2024</year>;<volume>74</volume>:<fpage>229</fpage>&#8208;<lpage>263</lpage>.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></ref><ref id="ame212548-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="ame212548-cit-0048"><string-name name-style="western"><surname>Riely</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Ettinger</surname><given-names>DS</given-names></string-name>, et&#160;al. <article-title>Non&#8208;small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2024</year>;<volume>22</volume>(<issue>4</issue>):<fpage>249</fpage>&#8208;<lpage>274</lpage>.<pub-id pub-id-type="pmid">38754467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2204.0023</pub-id></mixed-citation></ref><ref id="ame212548-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="ame212548-cit-0049"><string-name name-style="western"><surname>Hu</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Mi</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>YQ</given-names></string-name>, <string-name name-style="western"><surname>Mao&#8208;Ying</surname><given-names>QL</given-names></string-name>. <article-title>Prevention and treatment for chemotherapy&#8208;induced peripheral neuropathy: therapies based on CIPN mechanisms</article-title>. <source>Curr Neuropharmacol</source>. <year>2019</year>;<volume>17</volume>(<issue>2</issue>):<fpage>184</fpage>&#8208;<lpage>196</lpage>.<pub-id pub-id-type="pmid">28925884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X15666170915143217</pub-id><pub-id pub-id-type="pmcid">PMC6343206</pub-id></mixed-citation></ref><ref id="ame212548-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="ame212548-cit-0050"><string-name name-style="western"><surname>Casals&#8208;D&#237;az</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Casas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Navarro</surname><given-names>X</given-names></string-name>. <article-title>Changes of voltage&#8208;gated sodium channels in sensory nerve regeneration and neuropathic pain models</article-title>. <source>Restor Neurol Neurosci</source>. <year>2015</year>;<volume>33</volume>(<issue>3</issue>):<fpage>321</fpage>&#8208;<lpage>334</lpage>.<pub-id pub-id-type="pmid">25698112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/RNN-140444</pub-id></mixed-citation></ref><ref id="ame212548-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="ame212548-cit-0051"><string-name name-style="western"><surname>Velasco&#8208;Gonz&#225;lez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Coffeen</surname><given-names>U</given-names></string-name>. <article-title>Neurophysiopathological aspects of paclitaxel&#8208;induced peripheral neuropathy</article-title>. <source>Neurotox Res</source>. <year>2022</year>;<volume>40</volume>(<issue>6</issue>):<fpage>1673</fpage>&#8208;<lpage>1689</lpage>.<pub-id pub-id-type="pmid">36169871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-022-00582-8</pub-id></mixed-citation></ref><ref id="ame212548-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="ame212548-cit-0052"><string-name name-style="western"><surname>Cavalli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mammana</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nicoletti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bramanti</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mazzon</surname><given-names>E</given-names></string-name>. <article-title>The neuropathic pain: an overview of the current treatment and future therapeutic approaches</article-title>. <source>Int J Immunopathol Pharmacol</source>. <year>2019</year>;<volume>33</volume>:<elocation-id>8383</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2058738419838383</pub-id><pub-id pub-id-type="pmcid">PMC6431761</pub-id><pub-id pub-id-type="pmid">30900486</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>